GRANULES896.50

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹22,215 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity13.2013.5011.7011.70
Return on Assets7.348.027.717.71
Return on Capital Employed18.8616.9415.8015.80
Return on Invested Capital11.8112.0612.1613.16
Margins
EBITDA Margin18.9921.0922.0922.68
Operating Margin14.3916.0616.5716.57
Incremental Operating Margin-287.1219.15
Pretax Margin12.1414.7314.6315.64
Net Income Margin8.9911.1911.0911.76
Net Income to Common Margin9.4511.19
FCF Margin1.316.584.384.38
Additional
Effective Tax Rate25.9324.0324.2024.81
Dvd Payout Ratio8.967.256.12
Sustainable Growth Rate12.0212.5210.9811.70
Incremental Operating Margin %-287.1219.1530.52
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.